FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912112623> ?p ?o ?g. }

• W2912112623 endingPage "898" @default.
• W2912112623 startingPage "889" @default.
• W2912112623 abstract "BackgroundmAb114 is a single monoclonal antibody that targets the receptor-binding domain of Ebola virus glycoprotein, which prevents mortality in rhesus macaques treated after lethal challenge with Zaire ebolavirus. Here we present expedited data from VRC 608, a phase 1 study to evaluate mAb114 safety, tolerability, pharmacokinetics, and immunogenicity.MethodsIn this phase 1, dose-escalation study (VRC 608), conducted at the US National Institutes of Health (NIH) Clinical Center (Bethesda, MD, USA), healthy adults aged 18–60 years were sequentially enrolled into three mAb114 dose groups of 5 mg/kg, 25 mg/kg, and 50 mg/kg. The drug was given to participants intravenously over 30 min, and participants were followed for 24 weeks. Participants were only enrolled into increased dosing groups after interim safety assessments. Our primary endpoints were safety and tolerability, with pharmacokinetic and anti-drug antibody assessments as secondary endpoints. We assessed safety and tolerability in all participants who received study drug by monitoring clinical laboratory data and self-report and direct clinician assessment of prespecified infusion-site symptoms 3 days after infusion and systemic symptoms 7 days after infusion. Unsolicited adverse events were recorded for 28 days. Pharmacokinetic and anti-drug antibody assessments were completed in participants with at least 56 days of data. This trial is registered with ClinicalTrials.gov, number NCT03478891, and is active but no longer recruiting.FindingsBetween May 16, and Sept 27, 2018, 19 eligible individuals were enrolled. One (5%) participant was not infused because intravenous access was not adequate. Of 18 (95%) remaining participants, three (17%) were assigned to the 5 mg/kg group, five (28%) to the 25 mg/kg group, and ten (55%) to the 50 mg/kg group, each of whom received a single infusion of mAb114 at their assigned dose. All infusions were well tolerated and completed over 30–37 min with no infusion reactions or rate adjustments. All participants who received the study drug completed the safety assessment of local and systemic reactogenicity. No participants reported infusion-site symptoms. Systemic symptoms were all mild and present only in four (22%) of 18 participants across all dosing groups. No unsolicited adverse events occurred related to mAb114 and one serious adverse event occurred that was unrelated to mAb114. mAb114 has linear pharmacokinetics and a half-life of 24·2 days (standard error of measurement 0·2) with no evidence of anti-drug antibody development.InterpretationmAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings.FundingVaccine Research Center, US National Institute of Allergy and Infectious Diseases, and NIH. mAb114 is a single monoclonal antibody that targets the receptor-binding domain of Ebola virus glycoprotein, which prevents mortality in rhesus macaques treated after lethal challenge with Zaire ebolavirus. Here we present expedited data from VRC 608, a phase 1 study to evaluate mAb114 safety, tolerability, pharmacokinetics, and immunogenicity. In this phase 1, dose-escalation study (VRC 608), conducted at the US National Institutes of Health (NIH) Clinical Center (Bethesda, MD, USA), healthy adults aged 18–60 years were sequentially enrolled into three mAb114 dose groups of 5 mg/kg, 25 mg/kg, and 50 mg/kg. The drug was given to participants intravenously over 30 min, and participants were followed for 24 weeks. Participants were only enrolled into increased dosing groups after interim safety assessments. Our primary endpoints were safety and tolerability, with pharmacokinetic and anti-drug antibody assessments as secondary endpoints. We assessed safety and tolerability in all participants who received study drug by monitoring clinical laboratory data and self-report and direct clinician assessment of prespecified infusion-site symptoms 3 days after infusion and systemic symptoms 7 days after infusion. Unsolicited adverse events were recorded for 28 days. Pharmacokinetic and anti-drug antibody assessments were completed in participants with at least 56 days of data. This trial is registered with ClinicalTrials.gov, number NCT03478891, and is active but no longer recruiting. Between May 16, and Sept 27, 2018, 19 eligible individuals were enrolled. One (5%) participant was not infused because intravenous access was not adequate. Of 18 (95%) remaining participants, three (17%) were assigned to the 5 mg/kg group, five (28%) to the 25 mg/kg group, and ten (55%) to the 50 mg/kg group, each of whom received a single infusion of mAb114 at their assigned dose. All infusions were well tolerated and completed over 30–37 min with no infusion reactions or rate adjustments. All participants who received the study drug completed the safety assessment of local and systemic reactogenicity. No participants reported infusion-site symptoms. Systemic symptoms were all mild and present only in four (22%) of 18 participants across all dosing groups. No unsolicited adverse events occurred related to mAb114 and one serious adverse event occurred that was unrelated to mAb114. mAb114 has linear pharmacokinetics and a half-life of 24·2 days (standard error of measurement 0·2) with no evidence of anti-drug antibody development. mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings." @default.
• W2912112623 created "2019-02-21" @default.
• W2912112623 creator A5000950209 @default.
• W2912112623 creator A5003171862 @default.
• W2912112623 creator A5004545023 @default.
• W2912112623 creator A5005549616 @default.
• W2912112623 creator A5005928022 @default.
• W2912112623 creator A5006842014 @default.
• W2912112623 creator A5007027770 @default.
• W2912112623 creator A5007067447 @default.
• W2912112623 creator A5008829184 @default.
• W2912112623 creator A5009555393 @default.
• W2912112623 creator A5010190528 @default.
• W2912112623 creator A5010489661 @default.
• W2912112623 creator A5010514270 @default.
• W2912112623 creator A5011534601 @default.
• W2912112623 creator A5015206660 @default.
• W2912112623 creator A5018140265 @default.
• W2912112623 creator A5020230187 @default.
• W2912112623 creator A5020660628 @default.
• W2912112623 creator A5021055944 @default.
• W2912112623 creator A5021608465 @default.
• W2912112623 creator A5023293075 @default.
• W2912112623 creator A5023307172 @default.
• W2912112623 creator A5025227038 @default.
• W2912112623 creator A5025229803 @default.
• W2912112623 creator A5025725339 @default.
• W2912112623 creator A5025730704 @default.
• W2912112623 creator A5028814618 @default.
• W2912112623 creator A5030286131 @default.
• W2912112623 creator A5036040601 @default.
• W2912112623 creator A5038522604 @default.
• W2912112623 creator A5040048678 @default.
• W2912112623 creator A5040076878 @default.
• W2912112623 creator A5040628256 @default.
• W2912112623 creator A5041020193 @default.
• W2912112623 creator A5043620927 @default.
• W2912112623 creator A5044380940 @default.
• W2912112623 creator A5044479295 @default.
• W2912112623 creator A5048323392 @default.
• W2912112623 creator A5048473316 @default.
• W2912112623 creator A5049844442 @default.
• W2912112623 creator A5051357921 @default.
• W2912112623 creator A5052456314 @default.
• W2912112623 creator A5056353668 @default.
• W2912112623 creator A5057822521 @default.
• W2912112623 creator A5058077679 @default.
• W2912112623 creator A5059344251 @default.
• W2912112623 creator A5069835036 @default.
• W2912112623 creator A5069904142 @default.
• W2912112623 creator A5071657202 @default.
• W2912112623 creator A5073743424 @default.
• W2912112623 creator A5074086597 @default.
• W2912112623 creator A5075201763 @default.
• W2912112623 creator A5075202938 @default.
• W2912112623 creator A5077598738 @default.
• W2912112623 creator A5077962327 @default.
• W2912112623 creator A5078257989 @default.
• W2912112623 creator A5083450864 @default.
• W2912112623 creator A5083515370 @default.
• W2912112623 creator A5084292957 @default.
• W2912112623 creator A5088823637 @default.
• W2912112623 creator A5090586062 @default.
• W2912112623 date "2019-03-01" @default.
• W2912112623 modified "2023-10-06" @default.
• W2912112623 title "Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study" @default.
• W2912112623 cites W1966264059 @default.
• W2912112623 cites W1977020956 @default.
• W2912112623 cites W1993048073 @default.
• W2912112623 cites W2028463307 @default.
• W2912112623 cites W2043829974 @default.
• W2912112623 cites W2044168200 @default.
• W2912112623 cites W2054187786 @default.
• W2912112623 cites W2077149270 @default.
• W2912112623 cites W2080445973 @default.
• W2912112623 cites W2085818819 @default.
• W2912112623 cites W2094993149 @default.
• W2912112623 cites W2105521580 @default.
• W2912112623 cites W2110951885 @default.
• W2912112623 cites W2128406623 @default.
• W2912112623 cites W2130063921 @default.
• W2912112623 cites W2131169185 @default.
• W2912112623 cites W2136418784 @default.
• W2912112623 cites W2139749521 @default.
• W2912112623 cites W2168444132 @default.
• W2912112623 cites W2225294925 @default.
• W2912112623 cites W2274022023 @default.
• W2912112623 cites W2288202420 @default.
• W2912112623 cites W2293882857 @default.
• W2912112623 cites W2507513922 @default.
• W2912112623 cites W2544612685 @default.
• W2912112623 cites W2549455555 @default.
• W2912112623 cites W2785308733 @default.
• W2912112623 cites W2806465206 @default.
• W2912112623 cites W2807833333 @default.
• W2912112623 cites W2883658995 @default.
• W2912112623 doi "https://doi.org/10.1016/s0140-6736(19)30036-4" @default.
• W2912112623 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6436835" @default.

• next